Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HASSAN YOUSAF

Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine

NPI
1851754170
CMS profile
5700424
Location
WINSTON SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$85,175.67

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HASSAN YOUSAF

NPI 1851754170 · CMS profile ID 5700424

Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine

WINSTON SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851754170?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HASSAN YOUSAF, NPI 1851754170, CMS profile ID 5700424. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851754170?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HASSAN YOUSAF, NPI 1851754170, CMS profile ID 5700424. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851754170?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HASSAN YOUSAF, NPI 1851754170, CMS profile ID 5700424, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1851754170?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $85,175.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $3,400.0009/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206244508 CMS
AstraZeneca Pharmaceuticals LP $109.2009/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206266100 CMS
AstraZeneca Pharmaceuticals LP $67.2809/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206456110 CMS
AstraZeneca Pharmaceuticals LP $1,250.0009/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206589896 CMS
AstraZeneca Pharmaceuticals LP $1,250.0009/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206839833 CMS
GlaxoSmithKline, LLC. $50.4009/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190820048 CMS
GlaxoSmithKline, LLC. $2,600.0009/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1191586603 CMS
AstraZeneca Pharmaceuticals LP $164.6709/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206506475 CMS
AstraZeneca Pharmaceuticals LP $121.8409/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207187091 CMS
AstraZeneca Pharmaceuticals LP $186.7309/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207300066 CMS
GENZYME CORPORATION $44.6609/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233722046 CMS
GENZYME CORPORATION $4,896.0009/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233722048 CMS
GENZYME CORPORATION $196.3209/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233722050 CMS
GlaxoSmithKline, LLC. $22.7208/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191574904 CMS
GENZYME CORPORATION $82.7508/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233722036 CMS
GENZYME CORPORATION $3,060.0008/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233722038 CMS
Insmed, Inc. $18.3308/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186319552 CMS
AstraZeneca Pharmaceuticals LP $15.6308/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206943503 CMS
GlaxoSmithKline, LLC. $100.0808/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190424489 CMS
AstraZeneca Pharmaceuticals LP $24.2108/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206692893 CMS
GENZYME CORPORATION $107.9508/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233722030 CMS
GENZYME CORPORATION $4,896.0008/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233722032 CMS
GENZYME CORPORATION $92.4008/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233722034 CMS
GENZYME CORPORATION $32.4707/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233722026 CMS
GENZYME CORPORATION $19.0407/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233722024 CMS
GlaxoSmithKline, LLC. $7,150.0007/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190366120 CMS
GlaxoSmithKline, LLC. $10.5107/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190865113 CMS
Tempus AI, Inc $22.6807/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250353603 CMS
Viatris Specialty LLC $24.7507/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238515667 CMS
Grifols USA, LLC $22.0907/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249592209 CMS
GlaxoSmithKline, LLC. $14.9507/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190684607 CMS
GlaxoSmithKline, LLC. $48.1307/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190661941 CMS
GlaxoSmithKline, LLC. $147.8007/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191743452 CMS
Regeneron Healthcare Solutions, Inc. $18.6707/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213077286 CMS
GlaxoSmithKline, LLC. $21.7307/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190360247 CMS
Insmed, Inc. $24.0007/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186307960 CMS
AstraZeneca Pharmaceuticals LP $15.1906/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206739790 CMS
GlaxoSmithKline, LLC. $75.4506/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190337963 CMS
GlaxoSmithKline, LLC. $27.4406/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190380637 CMS
GlaxoSmithKline, LLC. $48.0206/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190463835 CMS
GlaxoSmithKline, LLC. $75.4506/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191301661 CMS
GlaxoSmithKline, LLC. $16.4606/21/2025 Gift No dispute reported Delay: No
Change: NEW
06/30/2026 1191338480 CMS
GlaxoSmithKline, LLC. $0.7506/21/2025 Gift No dispute reported Delay: No
Change: NEW
06/30/2026 1191507515 CMS
GlaxoSmithKline, LLC. $30.6406/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191558323 CMS
GlaxoSmithKline, LLC. $269.8606/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190802854 CMS
GlaxoSmithKline, LLC. $124.9906/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191062985 CMS
AstraZeneca Pharmaceuticals LP $250.0006/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206246122 CMS
GlaxoSmithKline, LLC. $5.1206/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190342135 CMS
GlaxoSmithKline, LLC. $1.4406/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190463103 CMS
GlaxoSmithKline, LLC. $3.4606/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190705580 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33.36 2
PY2022 $269.61 9
PY2023 $684.30 25
PY2024 $11,149.92 49
PY2025 $85,175.67 144

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,276.97 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 12/17/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675096
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 12/17/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675098
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 12/17/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675100
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 12/01/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220798061
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675078
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675080
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675082
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675084
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675086
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675088
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675090
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675092
Principal investigator 1 Boehringer Ingelheim International GmbH $22.50 11/19/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675094
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 11/01/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220798059
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12.09 10/01/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220798063
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675058
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675060
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675062
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675064
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675066
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675068
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675070
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675072
Principal investigator 1 Boehringer Ingelheim International GmbH $214.00 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675074
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 08/26/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675076
Principal investigator 1 Boehringer Ingelheim International GmbH $238.20 08/01/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675052
Principal investigator 1 Boehringer Ingelheim International GmbH $362.07 08/01/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675054
Principal investigator 1 Boehringer Ingelheim International GmbH $3,131.54 08/01/2025 Non-covered Recipient Entity
Southeastern Research Center
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220675056